{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T20:09:09Z","timestamp":1781294949219,"version":"3.54.1"},"publisher-location":"New York, NY","reference-count":91,"publisher":"Springer US","isbn-type":[{"value":"9781071618837","type":"print"},{"value":"9781071618844","type":"electronic"}],"license":[{"start":{"date-parts":[[2021,12,17]],"date-time":"2021-12-17T00:00:00Z","timestamp":1639699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,12,17]],"date-time":"2021-12-17T00:00:00Z","timestamp":1639699200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022]]},"DOI":"10.1007\/978-1-0716-1884-4_1","type":"book-chapter","created":{"date-parts":[[2021,12,16]],"date-time":"2021-12-16T16:04:44Z","timestamp":1639670684000},"page":"3-25","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Challenges for Vaccinologists in the First Half of the Twenty-First Century"],"prefix":"10.1007","author":[{"given":"Sunil","family":"Thomas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick J.","family":"Callaghan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rino","family":"Rappuoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,17]]},"reference":[{"key":"1_CR1","doi-asserted-by":"crossref","unstructured":"(2011) Microbiology by numbers. Nat Rev Microbiol 9:628","DOI":"10.1038\/nrmicro2644"},{"key":"1_CR2","doi-asserted-by":"crossref","unstructured":"(2019) Standing up to infectious disease. Nat Microbiol 4(1):1","DOI":"10.1038\/s41564-018-0331-3"},{"issue":"4 Suppl","key":"1_CR3","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1038\/nm1209","volume":"11","author":"SA Plotkin","year":"2005","unstructured":"Plotkin SA (2005) Vaccines: past, present and future. Nat Med 11(4 Suppl):S5\u2013S11","journal-title":"Nat Med"},{"key":"1_CR4","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1002\/emmm.201403876","volume":"6","author":"I Delany","year":"2014","unstructured":"Delany I, Rappuoli R, De Gregorio E (2014) Vaccines for the 21st century. EMBO Mol Med 6:708\u2013720","journal-title":"EMBO Mol Med"},{"issue":"5","key":"1_CR5","doi-asserted-by":"publisher","first-page":"264","DOI":"10.3855\/jidc.1204","volume":"4","author":"E Tognotti","year":"2010","unstructured":"Tognotti E (2010) The eradication of smallpox, a success story for modern medicine and public health: what lessons for the future? J Infect Dev Ctries 4(5):264\u2013266","journal-title":"J Infect Dev Ctries"},{"key":"1_CR6","unstructured":"World Health Organization, UNICEF (2010) Global immunization data"},{"key":"1_CR7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-1-4939-3387-7_1","volume":"1403","author":"PH Nambiar","year":"2016","unstructured":"Nambiar PH, Daza AD, Livornese LL Jr (2016) Clinical impact of vaccine development. Methods Mol Biol 1403:3\u201339","journal-title":"Methods Mol Biol"},{"key":"1_CR8","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/978-1-4939-3387-7_2","volume":"1403","author":"S Thomas","year":"2016","unstructured":"Thomas S, Dilbarova R, Rappuoli R (2016) Future challenges for vaccinologists. Methods Mol Biol 1403:41\u201355","journal-title":"Methods Mol Biol"},{"key":"1_CR9","unstructured":"World Health Organization (2008) The top 10 causes of death. Fact sheet no 310"},{"issue":"1","key":"1_CR10","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1139\/cjz-2018-0140","volume":"97","author":"H Jones","year":"2018","unstructured":"Jones H, Pekins PJ, Kantar L, Sidor I, Ellingwood D, Lichtenwalner A, O'Neal M (2018) Mortality assessment of calf moose (Alces alces) during successive years of winter tick (Dermacentor albipictus) epizootics in New Hampshire and Maine. Can J Zool 97(1):22\u201330","journal-title":"Can J Zool"},{"key":"1_CR11","doi-asserted-by":"publisher","first-page":"110046","DOI":"10.1016\/j.envres.2020.110046","volume":"191","author":"W Peng","year":"2020","unstructured":"Peng W, Ma NL, Zhang D, Zhou Q, Yue X, Khoo SC, Yang H, Guan R, Chen H, Zhang X, Wang Y, Wei Z, Suo C, Peng Y, Yang Y, Lam SS, Sonne C (2020) A review of historical and recent locust outbreaks: links to global warming, food security and mitigation strategies. Environ Res 191:110046","journal-title":"Environ Res"},{"issue":"4","key":"1_CR12","doi-asserted-by":"publisher","first-page":"ofz102","DOI":"10.1093\/ofid\/ofz102","volume":"6","author":"IG Balinda","year":"2019","unstructured":"Balinda IG, Sugrue DD, Ivers LC (2019) More than malnutrition: a review of the relationship between food insecurity and tuberculosis. Open Forum Infect Dis 6(4):ofz102","journal-title":"Open Forum Infect Dis"},{"issue":"10","key":"1_CR13","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1086\/587658","volume":"46","author":"P Katona","year":"2008","unstructured":"Katona P, Katona-Apte J (2008) The interaction between nutrition and infection. Clin Infect Dis 46(10):1582\u20131588","journal-title":"Clin Infect Dis"},{"issue":"1","key":"1_CR14","doi-asserted-by":"publisher","first-page":"342","DOI":"10.20411\/pai.v5i1.377","volume":"5","author":"S Thomas","year":"2020","unstructured":"Thomas S (2020) The structure of the membrane protein of SARS-CoV-2 resembles the sugar transporter SemiSWEET. Pathog Immun 5(1):342\u2013363","journal-title":"Pathog Immun"},{"key":"1_CR15","doi-asserted-by":"crossref","unstructured":"Thomas S (2021) Mapping the non-structural transmembrane proteins of SARS-CoV-2. J Comput Biol (in press)","DOI":"10.20944\/preprints202012.0366.v2"},{"issue":"10223","key":"1_CR16","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","volume":"395","author":"C Huang","year":"2020","unstructured":"Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395(10223):497\u2013506","journal-title":"Lancet"},{"issue":"13","key":"1_CR17","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1001\/jama.2021.1612","volume":"325","author":"W Zhang","year":"2021","unstructured":"Zhang W, Davis BD, Chen SS, Sincuir Martinez JM, Plummer JT, Vail E (2021) Emergence of a novel SARS-CoV-2 variant in Southern California. JAMA 325(13):1324\u20131326","journal-title":"JAMA"},{"issue":"6","key":"1_CR18","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1038\/sj.gt.3300930","volume":"6","author":"K Karik\u00f3","year":"1999","unstructured":"Karik\u00f3 K, Kuo A, Barnathan E (1999) Overexpression of urokinase receptor in mammalian cells following administration of the in vitro transcribed encoding mRNA. Gene Ther 6(6):1092\u20131100","journal-title":"Gene Ther"},{"issue":"7644","key":"1_CR19","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/nature21428","volume":"543","author":"N Pardi","year":"2017","unstructured":"Pardi N, Hogan MJ, Pelc RS, Muramatsu H, Andersen H, DeMaso CR, Dowd KA, Sutherland LL, Scearce RM, Parks R, Wagner W, Granados A, Greenhouse J, Walker M, Willis E, Yu JS, McGee CE, Sempowski GD, Mui BL, Tam YK, Huang YJ, Vanlandingham D, Holmes VM, Balachandran H, Sahu S, Lifton M, Higgs S, Hensley SE, Madden TD, Hope MJ, Karik\u00f3 K, Santra S, Graham BS, Lewis MG, Pierson TC, Haynes BF, Weissman D (2017) Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. Nature 543(7644):248\u2013251","journal-title":"Nature"},{"issue":"4","key":"1_CR20","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrd.2017.243","volume":"17","author":"N Pardi","year":"2018","unstructured":"Pardi N, Hogan MJ, Porter FW, Weissman D (2018) mRNA vaccines - a new era in vaccinology. Nat Rev Drug Discov 17(4):261\u2013279","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"1_CR21","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.immuni.2020.07.019","volume":"53","author":"D Laczk\u00f3","year":"2020","unstructured":"Laczk\u00f3 D, Hogan MJ, Toulmin SA, Hicks P, Lederer K, Gaudette BT, Casta\u00f1o D, Amanat F, Muramatsu H, Oguin TH 3rd, Ojha A, Zhang L, Mu Z, Parks R, Manzoni TB, Roper B, Strohmeier S, Tomb\u00e1cz I, Arwood L, Nachbagauer R, Karik\u00f3 K, Greenhouse J, Pessaint L, Porto M, Putman-Taylor T, Strasbaugh A, Campbell TA, PJC L, Tam YK, Sempowski GD, Farzan M, Choe H, Saunders KO, Haynes BF, Andersen H, Eisenlohr LC, Weissman D, Krammer F, Bates P, Allman D, Locci M, Pardi N (2020) A single immunization with nucleoside-modified mRNA vaccines elicits strong cellular and humoral immune responses against SARS-CoV-2 in mice. Immunity 53(4):724\u2013732.e7","journal-title":"Immunity"},{"key":"1_CR22","unstructured":"HIV.gov (2020) Global HIV & AIDS statistics - 2020 fact sheet"},{"issue":"1","key":"1_CR23","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jpainsymman.2015.02.006","volume":"50","author":"J Barroso","year":"2015","unstructured":"Barroso J, Leserman J, Harmon JL, Hammill B, Pence BW (2015) Fatigue in HIV-infected people: a three-year observational study. J Pain Symptom Manag 50(1):69\u201379","journal-title":"J Pain Symptom Manag"},{"key":"1_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.1002251","volume":"13","author":"JM Cuevas","year":"2015","unstructured":"Cuevas JM, Geller R, Gario R, Lopez-Aldeguer J, Sanjaun R (2015) Extremely high mutation rate of HIV-1 in vivo. PLoS Biol 13:e1002251","journal-title":"PLoS Biol"},{"key":"1_CR25","doi-asserted-by":"publisher","first-page":"269","DOI":"10.3390\/v11030269","volume":"11","author":"A Delannoy","year":"2019","unstructured":"Delannoy A, Poirier M, Bell B (2019) Cat and mouse: HIV transcription in latency, immune evasion and cure\/remission strategies. Viruses 11:269","journal-title":"Viruses"},{"key":"1_CR26","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/10439","volume":"5","author":"RC Desrosiers","year":"1999","unstructured":"Desrosiers RC (1999) Strategies used by human immunodeficiency virus that allow persistent viral replication. Nat Med 5:723\u2013725","journal-title":"Nat Med"},{"key":"1_CR27","unstructured":"Centers for Disease Control and prevention (2013) Viral Hemorrhagic Fevers (VHFs). https:\/\/www.cdc.gov\/vhf\/virus-families\/flaviviridae.html"},{"key":"1_CR28","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1515\/9781400883257-003","volume-title":"Virus: an illustrated guide to 101 incredible microbes","author":"M Roossinck","year":"2016","unstructured":"Roossinck M, Zimmer C (2016) Human viruses. In: Virus: an illustrated guide to 101 incredible microbes. Princeton University Press, Princeton, pp 50\u201397"},{"issue":"2","key":"1_CR29","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1080\/21645515.2017.1389363","volume":"14","author":"P Kaaijk","year":"2018","unstructured":"Kaaijk P, Luytjes W (2018) Are we prepared for emerging flaviviruses in Europe? Challenges for vaccination. Hum Vaccin Immunother 14(2):337\u2013344","journal-title":"Hum Vaccin Immunother"},{"issue":"12","key":"1_CR30","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1016\/j.vaccine.2014.01.040","volume":"32","author":"T Ishikawa","year":"2014","unstructured":"Ishikawa T, Yamanaka A, Konishi E (2014) A review of successful flavivirus vaccines and the problems with those flaviviruses for which vaccines are not yet available. Vaccine 32(12):1326\u20131337","journal-title":"Vaccine"},{"key":"1_CR31","doi-asserted-by":"publisher","first-page":"55","DOI":"10.15585\/mmwr.mm6503e1","volume":"65","author":"M Hennessey","year":"2016","unstructured":"Hennessey M, Fischer M, Staples JE (2016) Zika virus spreads to new areas \u2014 region of the Americas, May 2015\u2013January 2016. MMWR Morb Mortal Wkly Rep 65:55\u201358","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"1_CR32","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s11481-017-9743-8","volume":"12","author":"SS Pawitwar","year":"2017","unstructured":"Pawitwar SS, Dhar S, Tiwari S et al (2017) Overview on the current status of Zika virus pathogenesis and animal related research. J Neuroimmune Pharmacol 12:371\u2013388","journal-title":"J Neuroimmune Pharmacol"},{"issue":"6","key":"1_CR33","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S1473-3099(16)00095-5","volume":"16","author":"G Calvet","year":"2016","unstructured":"Calvet G, Aguiar RS, Melo AS, Sampaio SA, de Filippis I, Fabri A, Araujo ES, de Sequeira PC, de Mendon\u00e7a MC, de Oliveira L, Tschoeke DA, Schrago CG, Thompson FL, Brasil P, Dos Santos FB, Nogueira RM, Tanuri A, de Filippis AM (2016) Detection and sequencing of Zika virus from amniotic fluid of fetuses with microcephaly in Brazil: a case study. Lancet Infect Dis 16(6):653\u2013660","journal-title":"Lancet Infect Dis"},{"issue":"22","key":"1_CR34","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1056\/NEJMoa1601824","volume":"374","author":"RW Driggers","year":"2016","unstructured":"Driggers RW, Ho CY, Korhonen EM, Kuivanen S, J\u00e4\u00e4skel\u00e4inen AJ, Smura T, Rosenberg A, Hill DA, DeBiasi RL, Vezina G, Timofeev J, Rodriguez FJ, Levanov L, Razak J, Iyengar P, Hennenfent A, Kennedy R, Lanciotti R, du Plessis A, Vapalahti O (2016) Zika virus infection with prolonged maternal viremia and fetal brain abnormalities. N Engl J Med 374(22):2142\u20132151","journal-title":"N Engl J Med"},{"issue":"7","key":"1_CR35","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1055\/s-0036-1580089","volume":"33","author":"C Marrs","year":"2016","unstructured":"Marrs C, Olson G, Saade G, Hankins G, Wen T, Patel J, Weaver S (2016) Zika virus and pregnancy: a review of the literature and clinical considerations. Am J Perinatol 33(7):625\u2013639","journal-title":"Am J Perinatol"},{"issue":"4","key":"1_CR36","doi-asserted-by":"publisher","first-page":"487","DOI":"10.5114\/fmpcr.2016.63708","volume":"4","author":"M Ga\u0144czak","year":"2016","unstructured":"Ga\u0144czak M (2016) Zika virus infections from the perspective of the general practitioner. Family Med Primary Care Rev 4(4):487\u2013491","journal-title":"Family Med Primary Care Rev"},{"issue":"10120","key":"1_CR37","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/S0140-6736(17)33106-9","volume":"391","author":"K Modjarrad","year":"2018","unstructured":"Modjarrad K, Lin L, George SL, Stephenson KE, Eckels KH, De La Barrera RA, Jarman RG, Sondergaard E, Tennant J, Ansel JL, Mills K, Koren M, Robb ML, Barrett J, Thompson J, Kosel AE, Dawson P, Hale A, Tan CS, Walsh SR, Meyer KE, Brien J, Crowell TA, Blazevic A, Mosby K, Larocca RA, Abbink P, Boyd M, Bricault CA, Seaman MS, Basil A, Walsh M, Tonwe V, Hoft DF, Thomas SJ, Barouch DH, Michael NL (2018) Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials. Lancet 391(10120):563\u2013571","journal-title":"Lancet"},{"issue":"13","key":"1_CR38","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1056\/NEJMoa1506223","volume":"373","author":"SR Hadinegoro","year":"2015","unstructured":"Hadinegoro SR, Arredondo-Garc\u00eda JL, Capeding MR, Deseda C, Chotpitayasunondh T, Dietze R, Muhammad Ismail HI, Reynales H, Limkittikul K, Rivera-Medina DM, Tran HN, Bouckenooghe A, Chansinghakul D, Cort\u00e9s M, Fanouillere K, Forrat R, Frago C, Gailhardou S, Jackson N, Noriega F, Plennevaux E, Wartel TA, Zambrano B, Saville M, CYD-TDV Dengue Vaccine Working Group (2015) Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N Engl J Med 373(13):1195\u20131206","journal-title":"N Engl J Med"},{"issue":"6","key":"1_CR39","doi-asserted-by":"publisher","first-page":"a030700","DOI":"10.1101\/cshperspect.a030700","volume":"10","author":"SB Halstead","year":"2018","unstructured":"Halstead SB (2018) Which dengue vaccine approach is the most promising, and should we be concerned about enhanced disease after vaccination? There is only one true winner. Cold Spring Harb Perspect Biol 10(6):a030700","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"36","key":"1_CR40","doi-asserted-by":"publisher","first-page":"5137","DOI":"10.1016\/j.vaccine.2019.07.016","volume":"37","author":"A Wilder-Smith","year":"2019","unstructured":"Wilder-Smith A, Smith PG, Luo R, Kelly-Cirino C, Curry D, Larson H, Durbin A, Chu M, Tharmaphornpilas P, Ng LC, Sartori AMC, Luna EJA, Gubler DJ, Espa\u00f1a G, Yoon IK, Flasche S (2019) Pre-vaccination screening strategies for the use of the CYD-TDV dengue vaccine: a meeting report. Vaccine 37(36):5137\u20135146","journal-title":"Vaccine"},{"key":"1_CR41","doi-asserted-by":"publisher","first-page":"165","DOI":"10.12688\/wellcomeopenres.15507.1","volume":"4","author":"S Flasche","year":"2019","unstructured":"Flasche S, Wilder-Smith A, Hombach J, Smith PG (2019) Estimating the proportion of vaccine-induced hospitalized dengue cases among Dengvaxia vaccinees in the Philippines. Wellcome Open Res 4:165","journal-title":"Wellcome Open Res"},{"key":"1_CR42","doi-asserted-by":"crossref","unstructured":"L\u00f3pez-Medina E, Biswal S, Saez-Llorens X, Borja-Tabora C, Bravo L, Sirivichayakul C, Vargas LM, Alera MT, Vel\u00e1squez H, Reynales H, Rivera L, Watanaveeradej V, Rodriguez-Arenales EJ, Yu D, Espinoza F, Dietze R, Fernando L, Wickramasinghe P, Duarte Moreira E Jr, Fernando AD, Gunasekera D, Luz K, da Cunha RV, Tricou V, Rauscher M, Liu M, LeFevre I, Wallace D, Kosalaraksa P, Borkowski A, TIDES study group (2020) Efficacy of a dengue vaccine candidate (TAK-003) in healthy children and adolescents two years after vaccination. J Infect Dis jiaa761","DOI":"10.1093\/infdis\/jiaa761"},{"issue":"10234","key":"1_CR43","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/S0140-6736(20)30414-1","volume":"395","author":"S Biswal","year":"2020","unstructured":"Biswal S, Borja-Tabora C, Martinez Vargas L, Vel\u00e1squez H, Theresa Alera M, Sierra V, Johana Rodriguez-Arenales E, Yu D, Wickramasinghe VP, Duarte Moreira E Jr, Fernando AD, Gunasekera D, Kosalaraksa P, Espinoza F, L\u00f3pez-Medina E, Bravo L, Tuboi S, Hutagalung Y, Garbes P, Escudero I, Rauscher M, Bizjajeva S, LeFevre I, Borkowski A, Saez-Llorens X, Wallace D, TIDES study group (2020) Efficacy of a tetravalent dengue vaccine in healthy children aged 4-16 years: a randomised, placebo-controlled, phase 3 trial. Lancet 395(10234):1423\u20131433","journal-title":"Lancet"},{"issue":"4","key":"1_CR44","doi-asserted-by":"publisher","first-page":"698","DOI":"10.4269\/ajtmh.14-0268","volume":"92","author":"S Fernandez","year":"2015","unstructured":"Fernandez S, Thomas SJ, De La Barrera R, Im-Erbsin R, Jarman RG, Baras B, Toussaint JF, Mossman S, Innis BL, Schmidt A, Malice MP, Festraets P, Warter L, Putnak JR, Eckels KH (2015) An adjuvanted, tetravalent dengue virus purified inactivated vaccine candidate induces long-lasting and protective antibody responses against dengue challenge in rhesus macaques. Am J Trop Med Hyg 92(4):698\u2013708","journal-title":"Am J Trop Med Hyg"},{"issue":"1","key":"1_CR45","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1128\/CMR.00075-14","volume":"28","author":"E Robilotti","year":"2015","unstructured":"Robilotti E, Deresinski S, Pinsky B (2015) Norovirus. Clin Microbiol Rev 28(1):134\u2013164","journal-title":"Clin Microbiol Rev"},{"issue":"6","key":"1_CR46","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1080\/21645515.2018.1553594","volume":"15","author":"BD Hallowell","year":"2019","unstructured":"Hallowell BD, Parashar UD, Hall AJ (2019) Epidemiologic challenges in norovirus vaccine development. Hum Vaccin Immunother 15(6):1279\u20131283","journal-title":"Hum Vaccin Immunother"},{"issue":"6","key":"1_CR47","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0063485","volume":"8","author":"E Papafragkou","year":"2013","unstructured":"Papafragkou E, Hewitt J, Park GW, Greening G, Vinj\u00e9 J (2013) Challenges of culturing human norovirus in three-dimensional organoid intestinal cell culture models. PLoS One 8(6):e63485","journal-title":"PLoS One"},{"issue":"13","key":"1_CR48","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.121077","volume":"3","author":"L Kim","year":"2018","unstructured":"Kim L, Liebowitz D, Lin K, Kasparek K, Pasetti MF, Garg SJ, Gottlieb K, Trager G, Tucker SN (2018) Safety and immunogenicity of an oral tablet norovirus vaccine, a phase I randomized, placebo-controlled trial. JCI Insight 3(13):e121077","journal-title":"JCI Insight"},{"issue":"36","key":"1_CR49","doi-asserted-by":"publisher","first-page":"5842","DOI":"10.1016\/j.vaccine.2020.06.011","volume":"38","author":"J Treanor","year":"2020","unstructured":"Treanor J, Sherwood J, Cramer JP, Le Cam BN, Lin S, Baehner F, Borkowski A, NOR-204 investigators (2020) A phase 2 study of the bivalent VLP norovirus vaccine candidate in older adults; impact of MPL adjuvant or a second dose. Vaccine 38(36):5842\u20135850","journal-title":"Vaccine"},{"key":"1_CR50","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41572-018-0002-y","volume":"4","author":"F Krammer","year":"2018","unstructured":"Krammer F, Smith GJD, Fouchier RAM et al (2018) Influenza. Nat Rev Dis Primers 4:3","journal-title":"Nat Rev Dis Primers"},{"key":"1_CR51","unstructured":"Centers for Disease Control and Prevention (2019) Influenza (flu) https:\/\/www.cdc.gov\/flu\/about\/viruses\/types.htm"},{"issue":"3","key":"1_CR52","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.chom.2015.02.012","volume":"17","author":"K Houser","year":"2015","unstructured":"Houser K, Subbarao K (2015) Influenza vaccines: challenges and solutions. Cell Host Microbe 17(3):295\u2013300","journal-title":"Cell Host Microbe"},{"key":"1_CR53","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/s41573-019-0056-x","volume":"19","author":"CJ Wei","year":"2020","unstructured":"Wei CJ, Crank MC, Shiver J et al (2020) Next-generation influenza vaccines: opportunities and challenges. Nat Rev Drug Discov 19:239\u2013252","journal-title":"Nat Rev Drug Discov"},{"key":"1_CR54","doi-asserted-by":"publisher","first-page":"205031211983504","DOI":"10.1177\/2050312119835043","volume":"7","author":"B Gyawali","year":"2019","unstructured":"Gyawali B, Ramakrishna K, Dhamoon AS (2019) Sepsis: the evolution in definition, pathophysiology, and management. SAGE Open Med 7:2050312119835043","journal-title":"SAGE Open Med"},{"issue":"12","key":"1_CR55","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/S1473-3099(12)70239-6","volume":"12","author":"MM Levy","year":"2012","unstructured":"Levy MM, Artigas A, Phillips GS et al (2012) Outcomes of the surviving sepsis campaign in intensive care units in the USA and Europe: a prospective cohort study. Lancet Infect Dis 12(12):919\u2013924","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"1_CR56","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1111\/imj.14199","volume":"49","author":"K Thompson","year":"2019","unstructured":"Thompson K, Venkatesh B, Finfer S (2019) Sepsis and septic shock: current approaches to management. Intern Med J 49(2):160\u2013170","journal-title":"Intern Med J"},{"issue":"4","key":"1_CR57","doi-asserted-by":"publisher","first-page":"e00049","DOI":"10.1128\/CMR.00049-18","volume":"31","author":"LL Furfaro","year":"2018","unstructured":"Furfaro LL, Chang BJ, Payne MS (2018) Perinatal Streptococcus agalactiae epidemiology and surveillance targets. Clin Microbiol Rev 31(4):e00049\u2013e00018","journal-title":"Clin Microbiol Rev"},{"issue":"1","key":"1_CR58","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1038\/s41467-018-03847-z","volume":"9","author":"X Wang","year":"2018","unstructured":"Wang X, Thompson CD, Weidenmaier C, Lee JC (2018) Release of Staphylococcus aureus extracellular vesicles and their application as a vaccine platform. Nat Commun 9(1):1379","journal-title":"Nat Commun"},{"key":"1_CR59","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/978-90-481-9078-2_13","volume":"53","author":"AS Cross","year":"2010","unstructured":"Cross AS (2010) Development of an anti-endotoxin vaccine for sepsis. Subcell Biochem 53:285\u2013302","journal-title":"Subcell Biochem"},{"issue":"4","key":"1_CR60","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1111\/resp.13245","volume":"23","author":"B Zhu","year":"2018","unstructured":"Zhu B, Dockrell H, Ottenhoff T, Evans T, Zhang Y (2018) Tuberculosis vaccines: opportunities and challenges. Respirology 23(4):359\u2013368","journal-title":"Respirology"},{"issue":"9","key":"1_CR61","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/S2213-2600(19)30274-7","volume":"7","author":"H McShane","year":"2019","unstructured":"McShane H (2019) Insights and challenges in tuberculosis vaccine development. Lancet Respir Med 7(9):810\u2013819","journal-title":"Lancet Respir Med"},{"issue":"17","key":"1_CR62","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1056\/NEJMoa1803484","volume":"379","author":"O Van Der Meeren","year":"2018","unstructured":"Van Der Meeren O, Hatherill M, Nduba V, Wilkinson RJ, Muyoyeta M, Van Brakel E, Ayles HM, Henostroza G, Thienemann F, Scriba TJ, Diacon A, Blatner GL, Demoiti\u00e9 MA, Tameris M, Malahleha M, Innes JC, Hellstr\u00f6m E, Martinson N, Singh T, Akite EJ, Khatoon Azam A, Bollaerts A, Ginsberg AM, Evans TG, Gillard P, Tait DR (2018) Phase 2b controlled trial of M72\/AS01E vaccine to prevent tuberculosis. N Engl J Med 379(17):1621\u20131634","journal-title":"N Engl J Med"},{"issue":"25","key":"1_CR63","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1056\/NEJMoa1909953","volume":"381","author":"DR Tait","year":"2019","unstructured":"Tait DR, Hatherill M, Van Der Meeren O, Ginsberg AM, Van Brakel E, Salaun B, Scriba TJ, Akite EJ, Ayles HM, Bollaerts A, Demoiti\u00e9 MA, Diacon A, Evans TG, Gillard P, Hellstr\u00f6m E, Innes JC, Lempicki M, Malahleha M, Martinson N, Mesia Vela D, Muyoyeta M, Nduba V, Pascal TG, Tameris M, Thienemann F, Wilkinson RJ, Roman F (2019) Final analysis of a trial of M72\/AS01E vaccine to prevent tuberculosis. N Engl J Med 381(25):2429\u20132439","journal-title":"N Engl J Med"},{"issue":"12","key":"1_CR64","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1016\/j.vaccine.2017.01.055","volume":"35","author":"M Norrby","year":"2017","unstructured":"Norrby M, Vesikari T, Lindqvist L, Maeurer M, Ahmed R, Mahdavifar S, Bennett S, McClain JB, Shepherd BM, Li D, Hokey DA, Kromann I, Hoff ST, Andersen P, de Visser AW, Joosten SA, Ottenhoff THM, Andersson J, Brighenti S (2017) Safety and immunogenicity of the novel H4:IC31 tuberculosis vaccine candidate in BCG-vaccinated adults: two phase I dose escalation trials. Vaccine 35(12):1652\u20131661","journal-title":"Vaccine"},{"key":"1_CR65","doi-asserted-by":"publisher","first-page":"100313","DOI":"10.1016\/j.eclinm.2020.100313","volume":"21","author":"LG Bekker","year":"2020","unstructured":"Bekker LG, Dintwe O, Fiore-Gartland A, Middelkoop K, Hutter J, Williams A, Randhawa AK, Ruhwald M, Kromann I, Andersen PL, DiazGranados CA, Rutkowski KT, Tait D, Miner MD, Andersen-Nissen E, De Rosa SC, Seaton KE, Tomaras GD, McElrath MJ, Ginsberg A, Kublin JG, HVTN 602\/Aeras A-042 Protocol Team (2020) A phase 1b randomized study of the safety and immunological responses to vaccination with H4:IC31, H56:IC31, and BCG revaccination in Mycobacterium tuberculosis-uninfected adolescents in Cape Town, South Africa. EClinicalMedicine 21:100313","journal-title":"EClinicalMedicine"},{"issue":"2","key":"1_CR66","doi-asserted-by":"publisher","first-page":"e00083","DOI":"10.1128\/CMR.00083-18","volume":"33","author":"S Madison-Antenucci","year":"2020","unstructured":"Madison-Antenucci S, Kramer LD, Gebhardt LL, Kauffman E (2020) Emerging tick-borne diseases. Clin Microbiol Rev 33(2):e00083\u2013e00018","journal-title":"Clin Microbiol Rev"},{"issue":"11","key":"1_CR67","doi-asserted-by":"publisher","first-page":"4878","DOI":"10.1099\/ijsem.0.001445","volume":"66","author":"BS Pritt","year":"2016","unstructured":"Pritt BS, Respicio-Kingry LB, Sloan LM, Schriefer ME, Replogle AJ, Bjork J, Liu G, Kingry LC, Mead PS, Neitzel DF, Schiffman E, Hoang Johnson DK, Davis JP, Paskewitz SM, Boxrud D, Deedon A, Lee X, Miller TK, Feist MA, Steward CR, Theel ES, Patel R, Irish CL, Petersen JM (2016) Borrelia mayonii sp. nov., a member of the Borrelia burgdorferi sensu lato complex, detected in patients and ticks in the upper midwestern United States. Int J Syst Evol Microbiol 66(11):4878\u20134488","journal-title":"Int J Syst Evol Microbiol"},{"issue":"1","key":"1_CR68","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1097\/01.CCN.0000549627.98688.e2","volume":"14","author":"M Brennan","year":"2019","unstructured":"Brennan M, LeFevre F (2019) Necrotizing fasciitis: infection identification and management. Nursing Crit Care 14(1):6\u201311","journal-title":"Nursing Crit Care"},{"key":"1_CR69","unstructured":"WHO (2020) World malaria report 2020. 20 years of global progress and challenges. https:\/\/www.who.int\/teams\/global-malaria-programme\/reports\/world-malaria-report-2020"},{"issue":"9","key":"1_CR70","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1007943","volume":"15","author":"H Kumar","year":"2019","unstructured":"Kumar H, Tolia NH (2019) Getting in: the structural biology of malaria invasion. PLoS Pathog 15(9):e1007943","journal-title":"PLoS Pathog"},{"issue":"8","key":"1_CR71","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/embor.2013.103","volume":"14","author":"MN Wykes","year":"2013","unstructured":"Wykes MN (2013) Why haven't we made an efficacious vaccine for malaria? EMBO Rep 14(8):661","journal-title":"EMBO Rep"},{"issue":"9443","key":"1_CR72","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1016\/S0140-6736(04)17223-1","volume":"364","author":"PL Alonso","year":"2004","unstructured":"Alonso PL, Sacarlal J, Aponte JJ, Leach A, Macete E, Milman J, Mandomando I, Spiessens B, Guinovart C, Espasa M, Bassat Q, Aide P, Ofori-Anyinam O, Navia MM, Corachan S, Ceuppens M, Dubois MC, Demoiti\u00e9 MA, Dubovsky F, Men\u00e9ndez C, Tornieporth N, Ballou WR, Thompson R, Cohen J (2004) Efficacy of the RTS,S\/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet 364(9443):1411\u20131420","journal-title":"Lancet"},{"key":"1_CR73","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1038\/s41590-018-0228-6","volume":"19","author":"IA Cockburn","year":"2018","unstructured":"Cockburn IA et al (2018) Malaria prevention: from immunological concepts to effective vaccines and protective antibodies. Nat Immunol 19:1199\u20131211","journal-title":"Nat Immunol"},{"issue":"10233","key":"1_CR74","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1016\/S0140-6736(20)30815-1","volume":"395","author":"C Keating","year":"2020","unstructured":"Keating C (2020) The history of the RTS,S\/AS01 malaria vaccine trial. Lancet 395(10233):1336\u20131337","journal-title":"Lancet"},{"key":"1_CR75","first-page":"31","volume":"6736","author":"RTSS Clinical Trials Partnership","year":"2015","unstructured":"RTSS Clinical Trials Partnership (2015) Efficacy and safety of RTS,S\/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet 6736:31\u201345","journal-title":"Lancet"},{"issue":"7","key":"1_CR76","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0041451","volume":"7","author":"JM Reimer","year":"2012","unstructured":"Reimer JM, Karlsson KH, L\u00f6vgren-Bengtsson K, Magnusson SE, Fuentes A, Stertman L (2012) Matrix-M\u2122 adjuvant induces local recruitment, activation and maturation of central immune cells in absence of antigen. PLoS One 7(7):e41451","journal-title":"PLoS One"},{"key":"1_CR77","doi-asserted-by":"publisher","first-page":"46621","DOI":"10.1038\/srep46621","volume":"7","author":"KA Collins","year":"2017","unstructured":"Collins KA, Snaith R, Cottingham MG, Gilbert SC, Hill AVS (2017) Enhancing protective immunity to malaria with a highly immunogenic virus-like particle vaccine. Sci Rep 7:46621","journal-title":"Sci Rep"},{"key":"1_CR78","doi-asserted-by":"crossref","unstructured":"Venkatraman N et al (2019) Phase I assessments of first-in-human administration of a novel malaria anti-sporozoite vaccine candidate, R21 in matrix-M adjuvant, in UK and Burkinabe volunteers. Preprint at Medarxiv","DOI":"10.1101\/19009282"},{"key":"1_CR79","unstructured":"Mayer F (2020) The quest for a vaccine against malaria. Nature Portfolio. https:\/\/www.nature.com\/articles\/d42859-020-00021-8"},{"key":"1_CR80","unstructured":"Future Medicine (2020) Serum Institute joins hands with Novavax for malaria vaccine. https:\/\/futuremedicineindia.com\/serum-institute-joins-hands-with-novavax-for-malaria-vaccine\/"},{"key":"1_CR81","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s13045-019-0787-5","volume":"12","author":"T Jiang","year":"2019","unstructured":"Jiang T, Shi T, Zhang H et al (2019) Tumor neoantigens: from basic research to clinical applications. J Hematol Oncol 12:93","journal-title":"J Hematol Oncol"},{"key":"1_CR82","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/clpt.2011.281","volume":"91","author":"XY Shen","year":"2012","unstructured":"Shen XY, Orson FM, Kosten TR (2012) Vaccines against drug abuse. Clin Pharmacol Ther 91:60\u201370","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"1_CR83","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1002\/rmv.405","volume":"13","author":"A Takada","year":"2003","unstructured":"Takada A, Kawaoka Y (2003) Antibody-dependent enhancement of viral infection: molecular mechanisms and in vivo implications. Rev Med Virol 13(6):387\u2013398","journal-title":"Rev Med Virol"},{"issue":"1","key":"1_CR84","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1084\/jem.146.1.201","volume":"146","author":"SB Halstead","year":"1977","unstructured":"Halstead SB, O\u2019Rourke RJ (1977) Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody. J Exp Med 146(1):201\u2013217","journal-title":"J Exp Med"},{"key":"1_CR85","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1084\/jem.146.1.218","volume":"146","author":"SB Halstead","year":"1977","unstructured":"Halstead SB, O\u2019Rourke RJ, Allison AC (1977) Dengue viruses and mononuclear phagocytes. II. Identity of blood and tissue leukocytes supporting in vitro infection. J Exp Med 146:218\u2013229","journal-title":"J Exp Med"},{"key":"1_CR86","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1056\/NEJMoa1506223","volume":"373","author":"SR Hadinegoro","year":"2015","unstructured":"Hadinegoro SR, Arredondo-Garcia JL, Capeding MR et al (2015) Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N Engl J Med 373:1195\u20131206","journal-title":"N Engl J Med"},{"issue":"6334","key":"1_CR87","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1126\/science.aal4365","volume":"356","author":"SV Bardina","year":"2017","unstructured":"Bardina SV, Bunduc P, Tripathi S, Duehr J, Frere JJ, Brown JA, Nachbagauer R, Foster GA, Krysztof D, Tortorella D, Stramer SL, Garc\u00eda-Sastre A, Krammer F, Lim JK (2017) Enhancement of Zika virus pathogenesis by preexisting antiflavivirus immunity. Science 356(6334):175\u2013180","journal-title":"Science"},{"key":"1_CR88","doi-asserted-by":"publisher","first-page":"3704","DOI":"10.1128\/jvi.69.6.3704-3711.1995","volume":"69","author":"KH Siebelink","year":"1995","unstructured":"Siebelink KH, Tijhaar E, Huisman RC, Huisman W, de Ronde A, Darby IH et al (1995) Enhancement of feline immunodeficiency virus infection after immunization with envelope glycoprotein subunit vaccines. J Virol 69:3704\u20133711","journal-title":"J Virol"},{"key":"1_CR89","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/j.1600-0684.1991.tb00514.x","volume":"20","author":"R Le Grand","year":"1991","unstructured":"Le Grand R, Vogt G, Chapel A, Dormont D (1991) Antibody-dependent enhancement and neutralization pattern of sera from SIV-infected or HIV-2-vaccinated rhesus monkeys. J Med Primatol 20:172\u2013176","journal-title":"J Med Primatol"},{"issue":"8589","key":"1_CR90","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/S0140-6736(88)91657-1","volume":"331","author":"WE Robinson Jr","year":"1988","unstructured":"Robinson WE Jr, Montefiori DC, Mitchell WM (1988) Antibody-dependent enhancement of human immunodeficiency virus type 1 infection. Lancet 331(8589):790\u2013794","journal-title":"Lancet"},{"issue":"5853","key":"1_CR91","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1126\/science.318.5853.1048","volume":"318","author":"J Cohen","year":"2007","unstructured":"Cohen J (2007) AIDS research. Did Merck\u2019s failed HIV vaccine cause harm? Science 318(5853):1048\u20131049","journal-title":"Science"}],"container-title":["Methods in Molecular Biology","Vaccine Design"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-1884-4_1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,22]],"date-time":"2022-10-22T00:03:54Z","timestamp":1666397034000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-1884-4_1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,17]]},"ISBN":["9781071618837","9781071618844"],"references-count":91,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-1884-4_1","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,17]]},"assertion":[{"value":"17 December 2021","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}